United Kingdom to Build a New Cell and Gene Therapy Manufacturing Center
By LabMedica International staff writers
Posted on 05 Jan 2015
The United Kingdom (UK) Cell Therapy Catapult (Guy's Hospital; Great Maze Pond, London, UK) plans to build the new GBP 55-million Cell Therapy manufacturing center in the Stevenage Bioscience Catalyst campus (Stevenage, UK). Posted on 05 Jan 2015
Cell therapy and gene therapy use a patient's own cells to fight or prevent diseases such as cancer, and can replace the use of drugs or surgery.
The center which will open in 2017, is forecast to generate investment by international companies of GBP 1.2 billion (80% via export) by the year 2020, and up to 150 new jobs. The center will manufacture commercial supplies of advanced therapeutic medicinal products such as gene and cell therapies, as well as late-phase clinical trial equipment. The Cell Therapy Catapult will manage the center.
According to Iain Gray, Chief Executive of United Kingdom Government's Innovate UK (Swindon, Wiltshire, UK), “This is an exciting development for the Cell Therapy Catapult and an important next step in the establishment of the UK as a global manufacturing center for the cell therapy industry.”
Related Links:
Stevenage Bioscience Catalyst campus
Cell Therapy Catapult
Innovate UK